- US-listed companies
- UroGen Pharma Ltd.
UroGen Pharma Ltd.URGN
Market cap
$408.05M
P/E ratio
Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | |
Revenue | 8 | 1 | 0 | 12 | 48 | 64 |
Cost of revenue | 1 | 2 | - | 1 | 5 | 8 |
Gross profit | 8 | -1 | 0 | 11 | 43 | 57 |
Research and development expenses | - | - | 49 | 47 | 48 | 53 |
Selling, general and administrative expenses | - | - | - | 90 | 88 | 83 |
Operating loss | -20 | -77 | -109 | -127 | -92 | -79 |
Financing on prepaid forward obligation | - | - | - | - | 17 | 22 |
Interest expense on long-term debt | - | - | - | - | - | 8 |
Interest and other income, net | - | - | - | - | - | 1 |
Loss before income taxes | -20 | -76 | -105 | -125 | -109 | -108 |
Income tax expense | 0 | 0 | - | 3 | 1 | 2 |
Net Loss | -20 | -76 | -105 | -128 | -111 | -110 |
Net loss | -20 | -76 | -105 | -128 | -111 | -110 |
Unrealized (loss) on investments | - | - | 0 | -0 | -0 | -0 |
Comprehensive Loss | - | - | -105 | -128 | -111 | -110 |
Net loss per ordinary share - basic and diluted (in dollars per share) | - | - | - | - | - | -4.81 |